J Gynecol Oncol | Volume 7, Issue 1 | Research Article | Open Access
Rothnie K*, Yang J, Gorman M, Dicker S, Akerman M, Bhana D, Danziger M, Frimer M and Goldberg GL
Department of Gynecologic Oncology, Northwell Health, United States
Department of Obstetrics and Gynecology, Northwell, United States
City University of New York School of Medicine, 160 Convent Avenue, United States
Biostatistics Unit, Office of Academic Affairs, 1111 Marcus Avenue, United States
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States
*Correspondance to: Kersten Rothnie
Fulltext PDFObjectives: To investigate the long-term outcome of cervical cancer and its relationship with histopathology and pembrolizumab use. Methods: A multi-site retrospective cohort study on patients with cervical squamous cell cancer (SCC) and adenocarcinoma (AC). Results: 387 patients identified from 2004-2025. 294 (76%) had SCC and 93 (24%) had AC. 138 (35.7%) stage I, 100 (25.8%) stage II, 117 (30.2%) stage III, and 32 (8.3%) stage IV. HPV status was negative in 93 (23.9%) and positive in 150 (38.7%). PD-L1 status was negative in 13 (3.3%) and positive in 60 (15.5%). Most HPV and PD-L1 results were unknown (144, 37.4% and 314, 81.2%, respectively). Pembrolizumab was used in 52 (13.4%), (36.5% upfront, 63.5% recurrent). There was a significant difference in progression-free survival between receiving pembrolizumab vs. not (HR=4.59; 95% CI 2.79-7.56, p=<0.0001). There was no difference in overall survival for all-comers (HR=1.19; 95% CI 0.41-3.46, p=0.7402), nor for recurrent patients only (p=0.4424). In a subgroup analysis of stage III/IV patients (149, 38.5%), those treated with pembrolizumab vs. not had a significantly shorter median progression-free survival (17.9 vs 140.6 months, p<0.0001). Conclusions: In our patient population the use of pembrolizumab was associated with a worsened progression-free survival and no difference in overall survival. Our results differ from recently published randomized controlled trials, potentially due to the small number of patients who received pembrolizumab and an overall worse prognosis in stage III/IV patients regardless of treatment. Most patients receiving pembrolizumab had recurrent disease. These results prompt continued analysis of longitudinal outcomes at our institutions.
Cervical cancer; Vaccine; Pembrolizumab
Rothnie K, Yang J, Gorman M, Dicker S, Akerman M, Bhana D, et al. Long- Term Outcome of Patients Who Received Pembrolizumab During Treatment for Carcinoma of the Cervix. J Gynecol Oncol. 2026; 7(1): 1088.